Opaleye Management’s AMAG Pharmaceuticals AMAG Stock Holding History

Opaleye Management’s Portfolio AMAG Stock Details AMAG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-420,000	Closed	-$8.4M	–	58
2018 Q3	$8.4M	Hold	420,000	–	–	2.14%	14
2018 Q2	$8.19M	Buy	+420,000	New	+$9.29M	2.12%	14
2016 Q4	–	Sell	-15,000	Closed	-$368K	–	49
2016 Q3	$368K	Sell	15,000 -105,000	-88%	-$2.62M	0.19%	42
2016 Q2	$2.87M	Sell	120,000 -100,000	-45%	-$2.29M	1.92%	20
2016 Q1	$5.15M	Buy	220,000 +70,000	+47%	+$1.66M	3.21%	10
2015 Q4	$4.53M	Sell	150,000 -50,000	-25%	-$1.62M	1.89%	22
2015 Q3	$7.95M	Buy	200,000 +10,000	+5%	+$621K	3.91%	6
2015 Q2	$13.1M	Hold	190,000	–	–	5.22%	4
2015 Q1	$10.4M	Buy	+190,000	New	+$9.06M	4.82%	6

Other funds holding AMAG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Opaleye Management's AMAG Position: Q4 2018 in Review

Opaleye Management sold out of AMAG Pharmaceuticals (AMAG) in Q4 2018, closing a stake of 420,000 shares — an estimated $8.4M sold.

Opaleye Management first reported a position in AMAG in Q1 2015 and held it in 9 quarters. The position peaked at $13.1M in Q2 2015. 190 funds tracked by Wall St. Rank hold AMAG as of Q4 2018.

Opaleye Management reported no remaining AMAG Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Opaleye Management sold 420,000 AMAG Pharmaceuticals shares in Q4 2018, an estimated $8.4M.
Opaleye Management first reported a position in AMAG Pharmaceuticals in Q1 2015 and held it in 9 quarters.
Opaleye Management's AMAG Pharmaceuticals position peaked at $13.1M in Q2 2015.
190 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2018.

Based on Opaleye Management's 13F filing for Q4 2018, filed 14 Feb 2019.